Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473158 | 0.81 | EHMT2 (0.40) | — | |
| SCHEMBL31473150 | 0.79 | HDAC1 (0.40) | MAPTPKMSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31473148 | 0.77 | BRD4 (0.33) | SMN1; SMN2L3MBTL1KMT2AMEN1MAPK1 | |
| SCHEMBL31473132 | 0.76 | HCRTR1 (0.45) | ALDH1A1KDM4E | |
| SCHEMBL31473141 | 0.75 | CAPN1 (0.35) | ALDH1A1 | |
| SCHEMBL31473144 | 0.74 | HCRTR1 (0.43) | MAPTSMN1; SMN2LMNATP53L3MBTL1 | |
| SCHEMBL31473155 | 0.66 | FSHR (0.31) | — | |
| SCHEMBL31473157 | 0.63 | CYP2C9 (0.32) | CYP2C9CYP2C19TDP1 | |
| SCHEMBL12403600 | 0.62 | HTT (0.46) | MAPTSMN1; SMN2ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL14628034 | 0.61 | ALDH1A1 (0.45) | MAPTHSD17B10ALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008784-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES | VASTHERA CO LTD (KR) | 2026-01-08 | — | — | US | disclosed |
| CN-119403810-A | Compounds, pharmaceutical compositions containing them and their medical use for the treatment or prevention of vascular diseases | 瓦斯塞拉股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008784-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES | PRDX1, PRDX2, PRDX6 | MAPT 4875/4885HSD17B10 891/4885PKM 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.